Collaborative Arrangements and Licensing Agreements (Tables)

6 Months Ended

Jun. 30, 2019

Biogen [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three and six months ended June 30, 2019 and 2018, we earned the following revenue from our relationship with Biogen (in millions, except percentage amounts):

	Three Months Ended June 30,						Six Months Ended June 30,
	2019			2018			2019			2018
SPINRAZA royalties (commercial revenue)	$	70.5		$	56.7		$	130.2		$	97.7
R&D revenue		31.9			21.3			56.4			32.2
Total revenue from our relationship with Biogen	$	102.4		$	78.0		$	186.6		$	129.9
Percentage of total revenue		63	%		66	%		41	%		50	%

Roche [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three and six months ended June 30, 2019 and 2018, we earned the following revenue from our relationship with Roche (in millions, except percentage amounts):

	Three Months Ended June 30,						Six Months Ended June 30,
	2019			2018			2019			2018
R&D revenue	$	6.4		$	1.7		$	47.6		$	3.6
Percentage of total revenue		4	%		1	%		10	%		1	%

Novartis [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three and six months ended June 30, 2019 and 2018, we earned the following revenue from our relationship with Novartis (in millions, except percentage amounts):

	Three Months Ended June 30,						Six Months Ended June 30,
	2019			2018			2019			2018
R&D revenue	$	10.7		$	18.3		$	167.8		$	35.4
Percentage of total revenue		7	%		16	%		36	%		14	%